Achillion Pharma Q4 Net Loss Shrinks
The company has posted a revenue of $61,000, compared to negative revenue of $1.28m for the prior year period. The company adjusted its revenue to reflect revised estimate
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).
Battelle, an independent research and development organisation, has agreed to provide comprehensive pre-clinical research and development services, including infectious disease model development and product safety and efficacy evaluations